1. An open-label randomized controlled trial comparing the efficacy and safety of a 7-day triple therapy with bismuth versus 14-day standard triple therapy for Helicobacter pylori eradication in children and adolescentsAnja Šterbenc, Bor Vratanar, Eva Miler Mojškerc, Matjaž Homan, 2026, izvirni znanstveni članek Povzetek: Background: To achieve eradication rates > 90%, the ESPGHAN/NASPGHAN guidelines for pediatric Helicobacter pylori in-fection recommend tailored antimicrobial therapy using sufficiently high doses over 10–14 days. However, prolonged treatmentoften leads to suboptimal compliance in children, which is a major contributor to reduced eradication rates. To address this, weevaluated the efficacy and safety of a shorter, 7 day triple therapy with bismuth compared with the 14 day standard triple therapywithout bismuth in H. pylori infected children.Materials and Methods: From 2020 to 2024, we carried out a randomized controlled trial involving treatment-naïve childrenand adolescents (5–18 years old) with confirmed H. pylori infection. Eligible participants were randomly allocated to receiveeither a 7 day triple therapy with bismuth (bismuth subcitrate, a proton pump inhibitor [PPI], amoxicillin, plus clarithromycin/metronidazole) or a 14 day standard triple therapy (a PPI, amoxicillin, plus clarithromycin/metronidazole) without bismuth. Twomonths after completing therapy, treatment success was determined using either a two-step monoclonal stool antigen assay or aurea breath test. Any adverse events were documented using a structured questionnaire.Results: Seventy-three children were enrolled in the study. In the intention-to-treat analysis, eradication was achieved in 91%of children treated with the 7 day triple therapy with bismuth and 87% of those receiving the 14 day standard triple therapy(p = 0.695). Per-protocol eradication rates were 94% and 87%, respectively (p = 0.418). No serious adverse events were reported,and most adverse events were mild to moderate. A metallic taste was significantly more frequent in the 14 day standard tripletherapy group, while other adverse events occurred with similar frequency.Conclusions: Adding bismuth to a 7 day triple regimen achieved high eradication rates and a safety profile similar to 14 daystandard triple therapy, supporting its use as an effective and safe treatment option for pediatric H. pylori infection.
Ključne besede: treatment, eradication, Helicobacter pylori
Objavljeno v DiRROS: 14.01.2026; Ogledov: 146; Prenosov: 105
 Celotno besedilo (441,42 KB)
Gradivo ima več datotek! Več... |
2. Usefulness of rapid antigen testing for SARS-CoV-2 screening of healthcare workers : ǂa ǂpilot studyAnja Šterbenc, Viktorija Tomič, Urška Bidovec, Katja Vrankar, Aleš Rozman, Mihaela Zidarn, 2021, drugi znanstveni članki Povzetek: Background. Identification of infected healthcare workers (HCWs) is an important step in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) transmission control. Rapid antigen tests (RATs) are considered an important addition to molecular tests in diagnosing coronavirus disease 2019 (COVID-19), mainly because of their fast turnaround time, easier analytical procedure and lower price. However, real-life studies on the usefulness of such testing for screening of HCWs are limited. Methods. Physicians, nurses and hospital attendants currently working at the University Clinic of Respiratory and Allergic Diseases Golnik were invited to participate in the pilot study. Nasopharyngeal swabs were obtained three times per week for two consecutive weeks and tested with a point-of-care RAT and reverse transcription polymerase chain reaction (RT-PCR). Serum samples were obtained at the beginning of the study and 2 weeks after the last swab was collected to evaluate the serological status. Results. A total of 191 nasopharyngeal swabs from 36 HCWs were obtained. None of the samples tested was positive for the presence of SARS-CoV-2 antigen, whereas two HCWs tested positive on RT-PCR. Of these, one HCW had a newly identified SARS-CoV-2 infection, whereas RT-PCR probably detected a previous but recent infection in the other HCW. Conclusio.n Based on the results of this pilot study, it is unlikely that RAT will reliably detect novel SARS-CoV-2 infections among asymptomatic HCWs despite serial sampling. Although RT-PCR-based screening of HCWs may not be feasible due to high sample volume, molecular methods may identify SARS-CoV-2-infected HCWs already during the presymptomatic stage.
Ključne besede: SARS-CoV-2, health personnel, COVID-19 serological testing, real-time polymerase chain reaction, rapid antigen test, screening
Objavljeno v DiRROS: 28.05.2021; Ogledov: 2098; Prenosov: 742
 Povezava na datoteko |
3. |
4. |
